Navidea Biopharmaceuticals, Inc. | Ekinops
<div>Navidea Biopharmaceuticals, Inc. (OTC: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the company’s pivotal NAV3-33 clinical trial. Dr. Michael Blue, Navidea’s Chief Medical Officer, said "Results are not indicative of a commercially viable product.”<br> <br> Ekinops (Euronext Paris: EKI) (ISIN: FR0011466069), a leading supplier of optical transport and enterprise connectivity solutions for telecom operators and enterprises, today announced that Orange Business has chosen Ekinops …
Nid yw'r gyfres hon wedi ei throsglwyddo eto
Defnyddiwch STT.ai i drosysgrifo'r rhan hon gyda AI. Cael testun cywir gyda darganfod siaradwr, stampiau amser, ac allforio mewn amryw fformatau.